In a report released today, Justin Walsh from JonesTrading initiated coverage with a Buy rating on Prime Medicine, Inc. (PRME – Research Report) and a price target of $20.00. The company’s shares closed today at $12.00.
Walsh covers the Healthcare sector, focusing on stocks such as Vor Biopharma, Plus Therapeutics, and Theratechnologies. According to TipRanks, Walsh has an average return of -30.8% and a 20.91% success rate on recommended stocks.
Currently, the analyst consensus on Prime Medicine, Inc. is a Moderate Buy with an average price target of $21.00.
See today’s best-performing stocks on TipRanks >>
The company has a one-year high of $21.73 and a one-year low of $11.07. Currently, Prime Medicine, Inc. has an average volume of 383.9K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Prime Medicine Inc is a biotechnology company committed to delivering genetic therapies to address diseases by deploying gene editing technology, Prime Editing. The Prime Editing technology is a next-generation technology that can search and replace to restore normal genetic function in the genome and can treat a wide spectrum of diseases with high unmet medical needs.
Read More on PRME:
